Literature DB >> 23334207

Targeting eosinophils in allergy, inflammation and beyond.

Patricia C Fulkerson1, Marc E Rothenberg.   

Abstract

Eosinophils can regulate local immune and inflammatory responses, and their accumulation in the blood and tissue is associated with several inflammatory and infectious diseases. Thus, therapies that target eosinophils may help control diverse diseases, including atopic disorders such as asthma and allergy, as well as diseases that are not primarily associated with eosinophils, such as autoimmunity and malignancy. Eosinophil-targeted therapeutic agents that are aimed at blocking specific steps involved in eosinophil development, migration and activation have recently entered clinical testing and have produced encouraging results and insights into the role of eosinophils. In this Review, we describe recent advances in the development of first-generation eosinophil-targeted therapies and highlight strategies for using personalized medicine to treat eosinophilic disorders.

Entities:  

Mesh:

Year:  2013        PMID: 23334207      PMCID: PMC3822762          DOI: 10.1038/nrd3838

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  169 in total

1.  Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a.

Authors:  Ido Bachelet; Ariel Munitz; Francesca Levi-Schaffer
Journal:  J Allergy Clin Immunol       Date:  2006-06       Impact factor: 10.793

2.  Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells.

Authors:  Monica Rimoldi; Marcello Chieppa; Valentina Salucci; Francesca Avogadri; Angelica Sonzogni; Gianluca M Sampietro; Angelo Nespoli; Giuseppe Viale; Paola Allavena; Maria Rescigno
Journal:  Nat Immunol       Date:  2005-04-10       Impact factor: 25.606

3.  Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.

Authors:  E R Siemers; J F Quinn; J Kaye; M R Farlow; A Porsteinsson; P Tariot; P Zoulnouni; J E Galvin; D M Holtzman; D S Knopman; J Satterwhite; C Gonzales; R A Dean; P C May
Journal:  Neurology       Date:  2006-02-28       Impact factor: 9.910

Review 4.  The eosinophil: the cell and its weapons, the cytokines, its locations.

Authors:  Harsha H Kariyawasam; Douglas S Robinson
Journal:  Semin Respir Crit Care Med       Date:  2006-04       Impact factor: 3.119

Review 5.  The eosinophil.

Authors:  Marc E Rothenberg; Simon P Hogan
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

6.  The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils.

Authors:  Ariel Munitz; Ido Bachelet; Ron Eliashar; Alessandro Moretta; Lorenzo Moretta; Francesca Levi-Schaffer
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

7.  Eosinophilic differentiation is promoted by blockage of Notch signaling with a gamma-secretase inhibitor.

Authors:  Jin Hyun Kang; Da Hye Lee; Jong Soo Lee; Hai Joong Kim; Jin Woo Shin; Young Han Lee; Young Seek Lee; Choon-Sik Park; Il Yup Chung
Journal:  Eur J Immunol       Date:  2005-10       Impact factor: 5.532

Review 8.  Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.

Authors:  S T Holgate; R Djukanović; T Casale; J Bousquet
Journal:  Clin Exp Allergy       Date:  2005-04       Impact factor: 5.018

9.  Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis.

Authors:  Carine Blanchard; Ning Wang; Keith F Stringer; Anil Mishra; Patricia C Fulkerson; J Pablo Abonia; Sean C Jameson; Cassie Kirby; Michael R Konikoff; Margaret H Collins; Mitchell B Cohen; Rachel Akers; Simon P Hogan; Amal H Assa'ad; Philip E Putnam; Bruce J Aronow; Marc E Rothenberg
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

10.  Identification of eosinophil lineage-committed progenitors in the murine bone marrow.

Authors:  Hiromi Iwasaki; Shin-ichi Mizuno; Robin Mayfield; Hirokazu Shigematsu; Yojiro Arinobu; Brian Seed; Michael F Gurish; Kiyoshi Takatsu; Koichi Akashi
Journal:  J Exp Med       Date:  2005-06-13       Impact factor: 14.307

View more
  152 in total

1.  Dusp5 negatively regulates IL-33-mediated eosinophil survival and function.

Authors:  Derek A Holmes; Jung-Hua Yeh; Donghong Yan; Min Xu; Andrew C Chan
Journal:  EMBO J       Date:  2014-11-14       Impact factor: 11.598

2.  Autoimmunity to neuroretina in the concurrent absence of IFN-γ and IL-17A is mediated by a GM-CSF-driven eosinophilic inflammation.

Authors:  So Jin Bing; Phyllis B Silver; Yingyos Jittayasothorn; Mary J Mattapallil; Chi-Chao Chan; Reiko Horai; Rachel R Caspi
Journal:  J Autoimmun       Date:  2020-06-24       Impact factor: 7.094

Review 3.  Immune-mediated processes in neurodegeneration: where do we stand?

Authors:  Marc Fakhoury
Journal:  J Neurol       Date:  2016-02-12       Impact factor: 4.849

4.  The Effect of Methotrexate on Serum Levels of Trace/Mineral Elements in Patients with Psoriatic Arthritis.

Authors:  Yue Gao; Xia Li; Tao Liu; Zheng Liu
Journal:  Biol Trace Elem Res       Date:  2021-01-15       Impact factor: 3.738

Review 5.  Molecular, genetic, and cellular bases for treating eosinophilic esophagitis.

Authors:  Marc E Rothenberg
Journal:  Gastroenterology       Date:  2015-02-07       Impact factor: 22.682

6.  Structural basis for sulfation-dependent self-glycan recognition by the human immune-inhibitory receptor Siglec-8.

Authors:  Johannes M Pröpster; Fan Yang; Said Rabbani; Beat Ernst; Frédéric H-T Allain; Mario Schubert
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-29       Impact factor: 11.205

7.  Update on Eosinophil Interaction with Mast Cells: The Allergic Effector Unit.

Authors:  Roopesh Singh Gangwar; Hadas Pahima; Pier Giorgio Puzzovio; Francesca Levi-Schaffer
Journal:  Methods Mol Biol       Date:  2021

8.  Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.

Authors:  Jonathan Steinfeld; Eric S Bradford; Judith Brown; Stephen Mallett; Steven W Yancey; Praveen Akuthota; Maria C Cid; Gerald J Gleich; David Jayne; Paneez Khoury; Carol A Langford; Peter A Merkel; Frank Moosig; Ulrich Specks; Peter F Weller; Michael E Wechsler
Journal:  J Allergy Clin Immunol       Date:  2018-12-19       Impact factor: 10.793

Review 9.  Biologic therapies targeting eosinophils: current status and future prospects.

Authors:  Fanny Legrand; Amy D Klion
Journal:  J Allergy Clin Immunol Pract       Date:  2015 Mar-Apr

10.  Carbonic anhydrase IV is expressed on IL-5-activated murine eosinophils.

Authors:  Ting Wen; Melissa K Mingler; Benjamin Wahl; M Eyad Khorki; Oliver Pabst; Nives Zimmermann; Marc E Rothenberg
Journal:  J Immunol       Date:  2014-05-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.